TabsDetailsBasic DetailsDate: Tuesday, July 14, 2015Type: PublicationMedical Product: intravenous immune globulin (IGIV)Health Outcome(s): hemolysisDescription: This article describes a project that used Mini-Sentinel data to expand FDA’s understanding of hemolysis post- intravenous immune globulin (IGIV) administration. Read More Materials: Transfusion, 55: S28–S35. doi: 10.1111/trf.13116ContributorsAuthor(s): Scott K. Winiecki MD; Bethany Baer MD; Wambui Chege MD; Christopher Jankosky MD; Paul D. Mintz MD; Meghan A. Baker MD, ScD; Tiffany S. Woodworth MPH; Michael D. Nguyen MDCorresponding Author: S. Winiecki, FDA Center for Biologics Evaluation and Research, 10903 New Hampshire Avenue, WO71-1025, Silver Spring, MD; e-mail: scott.winiecki@fda.hhs.gov
